Cytometry Data Analysis Patents: Who Leads, Where the Gaps Are 2026
Cytometry data analysis and standards patents: who leads and where the claim space is still open
Concentrated at the top. The five leading assignees hold 36.9% of all 1,021 records in scope, and the top ten hold 51.5% — filing here is not evenly spread. Filings climbed from 71 in 2017 to a peak of 125 in 2020, then declined from 103 in 2021 to 65 in 2024 — a 37% drop over that three-year window. 2025 and 2026 figures are still filling in due to publication lag and should not be read as a continued fall.
- 1BECTON DICKINSON & CO209
- 2CRISPR THERAPEUTICS AG47
- 3DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS46
- 4UNIVERSITY OF HEIDELBERG41
- 5FLOWJO LLC34
See the full cytometry data analysis and standards analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
How concentrated is the patent landscape for cytometry data analysis?
It is moderately concentrated. The five leading assignees together hold 36.9% of all 1,021 records in scope, and the top ten hold 51.5%. That leaves roughly half the field distributed across a long tail of the remaining ranked assignees and unranked filers, so a newcomer is not necessarily boxed out, but the top few players have built substantial claim density that any new filing needs to be checked against.
Are cytometry data analysis patent filings still growing?
Filings peaked at 125 in 2020 and then declined from 103 in 2021 to 65 in 2024, a 37% drop over that span. That is a genuine cooling rather than a plateau. However, 2025 and 2026 figures are still incomplete because publication typically lags filing by about 18 months, so it would be premature to describe the field as currently shrinking based on the most recent one or two years alone.
What does WO2026017796A1 cover and does it block related work?
WO2026017796A1, filed by Medical University – Plovdiv and published in early 2026, describes a system for measuring minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia using multiparameter flow cytometry, with an acquisition subsystem, a control and file-generation subsystem, and an analytical subsystem. It is a recent, narrowly targeted clinical application rather than a foundational platform claim. Anyone working on MRD quantification in this specific leukemia subtype using multiparameter flow cytometry should read its claims closely, but it does not appear to reach broader cytometry data-analysis methods generally.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cytometry Data Analysis and Standards covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.